Genome-Based Vaccine Development: A Short Cut for the Future

  • Danilo Gomes Moriel
  • Maria Scarselli
  • Laura Serino
  • Marirosa Mora
  • Rino Rappuoli
  • Vega Masignani
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 655)


Bacterial infectious diseases remain a major cause of deaths and disabilities in the world. Although conventional vaccinology approaches were successful in conferring protection against several diseases, they failed in providing efficient vaccines against many others. Together to the sequencing of the first genome, a new chapter in the vaccinology history started to be written. Reverse vaccinology changed the way to think about vaccine development, using the information provided by the microorganisms’ genome against themselves. Since then, reverse vaccinology has evolved and helped researchers to overcome the limits of the conventional vaccinology approaches and led to the discovery and development of novel vaccines concerning emerging diseases, like Neisseria meningitidis B and Streptococcus agalactiae. A lot of work must be done, but deciphering the information provided by genome sequences and using it to better understand the host-pathogen interactions has proved to be the key for protection.


Vaccine Development Capsular Polysaccharide Core Genome Neisseria Meningitidis Bacillus Anthracis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fraser CM, Rappuoli R. Application of microbial genomic science to advanced therapeutics. Annu Rev Med 2005; 56:459–474.CrossRefPubMedGoogle Scholar
  2. 2.
    FDA. Vaccines licensed for immunization and distribution in the USA. vaccine/licvacc.htm.Accessed in 08/13/2007.Google Scholar
  3. 3.
    André FE. Vaccinology: past achievements, present roadblocks and future promises. Vaccine 2003; 21:593–595.CrossRefPubMedGoogle Scholar
  4. 4.
    Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007; 6:404–414.CrossRefPubMedGoogle Scholar
  5. 5.
    Rappuoli R. Reverse Vaccinology. Curr Opin Microbiol 2000; 3:445–450.CrossRefPubMedGoogle Scholar
  6. 6.
    Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11(4 Suppl):S5–S11.CrossRefPubMedGoogle Scholar
  7. 7.
    Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816–1820.CrossRefPubMedGoogle Scholar
  8. 8.
    Mora M, Veggi D, Santini L et al. Reverse vaccinology. Drug Discov Today 2003; 8(10):459–464.CrossRefPubMedGoogle Scholar
  9. 9.
    Tettelin H, Masignani V, Cieslewicz MJ et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci USA 2002; 99:12391–12396.CrossRefPubMedGoogle Scholar
  10. 10.
    Maione D, Margarit I, Rinaudo CD et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005; 309:148–150.CrossRefPubMedGoogle Scholar
  11. 11.
    Wizemann TM, Heinrichs JH, Adamou JE et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001; 69:1593–1598.CrossRefPubMedGoogle Scholar
  12. 12.
    Ariel N, Zvi A, Grosfeld H et al. Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect Immun 2002; 70:6817–6827.CrossRefPubMedGoogle Scholar
  13. 13.
    Montigiani S, Falugi F, Scarselli M et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 2002; 70:368–379.CrossRefPubMedGoogle Scholar
  14. 14.
    Ross BC, Czajkowski L, Hocking D et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 2001; 19: 4135–4142.CrossRefPubMedGoogle Scholar
  15. 15.
    Tettelin H, Medini D, Donati C et al. Towards a universal group B Streptococcus vaccine using multistrain genome analysis. Expert Rev Vaccines 2006; 5(5):687–694.CrossRefPubMedGoogle Scholar
  16. 16.
    Medini D, Donati C, Tettelin H et al. The microbial pan-genome. Curr Opin Genet Dev 2005; 15:589–594.CrossRefPubMedGoogle Scholar
  17. 17.
    Mora M, Donati C, Medini D et al. Microbial genomes and vaccine design: refinements to the classical riverse vaccinology approach. Curr Opin in Microbiol 2006; 9:532–536.CrossRefGoogle Scholar
  18. 18.
    Alekshun MN, Levy SB. Commensal upon us. Biochem Pharmacol 2006; 71:893–900.CrossRefPubMedGoogle Scholar
  19. 19.
    O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7(7):688–693.CrossRefPubMedGoogle Scholar
  20. 20.
    Dagan R. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otoryngology: the case of acute otitis media. Curr Opin Otoryngol Head Neck Surg 2004; 12(6):488–494.CrossRefGoogle Scholar
  21. 21.
    Satola SW, Schirmer PL, Farley MM. Genetic analysis of the capsule locus of Haemophilus influenzae serotype f. Infect Immun 2003; 71(12):7202–7207.CrossRefPubMedGoogle Scholar
  22. 22.
    NCBI Microbial Genomes. html. Accessed in 08/13/2007.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Danilo Gomes Moriel
    • 1
  • Maria Scarselli
    • 1
  • Laura Serino
    • 1
  • Marirosa Mora
    • 1
  • Rino Rappuoli
    • 1
  • Vega Masignani
    • 1
  1. 1.Novartis VaccinesSienaItaly

Personalised recommendations